Genital warts are the visible manif...

Genital warts are the visible manifestation of infection from one or more of the nearly 100 recognized human papillomaviruses (HPVs) Visible genital warts typically are caused on HPV types 6 and 11 which rarely are associated with invasive squamous solitary abode; squalid carcinoma of the external genitalia. (1) HPV shadows 16, 18, 31, 33, and 35 have been plant in genital warts and are associated with squamous intraepithelial neoplasia (1); models 16 and 18 are associated principally strongly with malignant potential. (2) These virus exemplars also are associated with vaginal, anal, and cervical intraepithelial dysplasia, and squamous solitary abode; squalid carcinoma.

Drug treatment of genital warts (3) and management of anorectal warts (4) have been addressed previously. This article provides an updated overview of the management of genital warts.

Diagnosis

Diagnosis of genital and anal warts is primarily clinical. The differential diagnosis includes benign or malignant neoplasm (eg squamous small cavity carcinoma in situ, Bowen's disease); molluscum contagiosum (especially in patients with human immunodeficiency virus [HIV]); condyloma lata; fibroepitheliomas; and pearly penile papules. Genital warts typically existing as flesh-colored, exophytic lesions forward the external genitalia, including the penis, vulva, scrotum perineum, and perianal skin. External warts can appear as small jolts or they may be flat, verrucous, or pedunculated. Les commonly warts can appear as reddish or brown even raised papules (Figure 1) or as dome-shaped lesions of 1 to 4 mm in succession keratinized skin (5,6) (Figure 2)

[FIGURES 1-2 OMITTED]

Internal warts can affect the mucous membranes of the vagina, urethra, anus, and aperture Intra-anal warts are present primarily in patients who have had receptive anal intercourse, although perianal warts can be met with in men or women who have no history of anal intercourse. Patients with internal warts may have discomfort, pain, bleeding, or difficulty with intercourse; these symptoms are more customary in patients with larger, cauliflower-like lesions. Urethral lesions may impair the passage of bodily fluids.

Diagnosis at biopsy and viral typing is not praiseed for patients with routine or typical lesions. (1) Biopsy is indicated if the diagnosis is uncertain or if the patient is immunocompromised; has a poor answer to appropriate therapy; has warts that are pigmented, indurated, fixed, or ulcerated; or is at high risk for HPV-related malignancy (eg chronic genital warts, tobacco use, history of abnormal Papanicolaou [Pap] smears). The part of HPV testing in women with abnormal Pap smears has been reviewed previously. (7)

Treatment Options and Methods

Untreated visible genital warts may unfold spontaneously, remain the same, or increase in size. The primary treatment goal is removal of symptomatic warts. near evidence suggests that treatment also may diminish the persistence of HPV DNA in genital tissue, and therefore may restore infectivity. (1) However, there is publicly no evidence that treatment of genital warts has a favorable impact forward the incidence of cervical and genital cancer, (1) and there have been no controll studies onward the effects of treatment of external genital warts and HPV transmission rates. (8)

The choice of therapy is based onward the number, size, site, and morphology of lesions, as well as patient estimation treatment cost, convenience, adverse weights and physician experience. Assuming that the diagnosis is certain, switching to a novel treatment modality is appropriate if there is no answer after three treatment cycles. Routine follow-up at sum of two units to three months is advised to monitor answer to therapy and evaluate for the having recourse (1)

Treatment orders can be chemical or ablative. The mechanism of action for each treatment rule is summarized in Table 1 (9) and treatment courses and periods are summarized in Table 2 Typical answer rates, adverse effect rates, and the having recourse risks are summarized in Table 3 (8-13); the reply rate for all treatments is approximately 60 to 90 percent and the reply rate for placebo is naught to 50 percent. (8,11)

CHEMICAL TREATMENTS (PATIENT-APPLIED)

Podofilox (Condylox) Podofilox is a 05 percent gel or solution containing purified extract of the greatest in number active compound of podophyllin. To preclude local irritation, patients should allow the solution to craving drink before moving around. The solution should be applied with a cotton swab; gel should be applied with a finger. near physicians prefer to perform the initial application. Podofilox is not commended for treatment of perianal, rectal, urethral, or vaginal lesions. Five randomized trials comparing podofilox with podophyllin set no difference in wart clearance rates. (8)

Imiquimod (Aldara). Imiquimod 5 percent cream is a topical cell-mediated immune answer modifier that comes in single-use packets. Patients should apply a thin layer to external, visible warts, then scrape in the cream until it vanishes. The area is washed with soap and water six to 10 hours after treatment. Imiquimod may weaken condoms and diaphragms, and sexual contact is not commended while the cream is forward the skin.